
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4480431/publications.pdf Version: 2024-02-01



Ι μις Βιμανία

#	Article	IF	CITATIONS
1	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, 611-621.e9.	4.4	17
2	Room for Improvement in the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2022, 56, e98-e108.	2.2	36
3	Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?. GastroenterologÃa Y HepatologÃa, 2022, 45, 697-705.	0.5	5
4	P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU. Journal of Crohn's and Colitis, 2022, 16, i496-i498.	1.3	0
5	P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, i474-i475.	1.3	0
6	Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology, 2022, 76, 1617-1633.	7.3	15
7	P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU. Journal of Crohn's and Colitis, 2022, 16, i491-i493.	1.3	2
8	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.7	119
9	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	3.7	11
10	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). Journal of Clinical Medicine, 2022, 11, 1658.	2.4	13
11	Incidence and evolution of foreign body impaction in the upper gastrointestinal tract and its relationship with eosionophilic oesophagitis. GastroenterologÃa Y HepatologÃa, 2022, 45, 274-281.	0.5	2
12	Beneficial effect of ursodeoxycholic acid in patients with acyl oA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia. Hepatology, 2022, 76, 1259-1274.	7.3	8
13	Investigación clÃnica independiente: afición o profesión. GastroenterologÃa Y HepatologÃa, 2022, 45, 786-787.	0.5	0
14	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	4.4	15
15	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. Biomedicines, 2022, 10, 727.	3.2	4
16	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 585-604.	17.8	15
17	Novel genes and sex differences in COVID-19 severity. Human Molecular Genetics, 2022, 31, 3789-3806.	2.9	38
18	IMPACT OF FIT-BASED CRC POPULATION SCREENING PROGRAM ON THE MANAGEMENT OF PT1 COLORECTAL CANCER. Gastrointestinal Endoscopy, 2022, 95, AB165-AB166.	1.0	0

#	Article	IF	CITATIONS
19	Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). Journal of Clinical Medicine, 2022, 11, 3544.	2.4	7
20	A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients. Metabolites, 2022, 12, 550.	2.9	9
21	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. Journal of Hepatology, 2022, 77, 991-1004.	3.7	22
22	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. Hepatology, 2021, 73, 186-203.	7.3	7
23	Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A communityâ€based cohort study. United European Gastroenterology Journal, 2021, 9, 256-267.	3.8	15
24	Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Digestive Diseases and Sciences, 2021, 66, 2014-2023.	2.3	28
25	Surgery and emergency gastrointestinal endoscopy during the Covid-19 pandemic. GastroenterologÃa Y HepatologÃa, 2021, 44, 294-296.	0.5	6
26	Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 433-463.	22.4	63
27	Prediction of liver iron overload in the Basque country (Spain) in patients referred for hyperferritinemia. Digestive and Liver Disease, 2021, 53, 137-138.	0.9	0
28	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. Journal of Hepatology, 2021, 74, 394-406.	3.7	14
29	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut, 2021, 70, 40-54.	12.1	139
30	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut, 2021, 70, 1345-1361.	12.1	59
31	Pterostilbene modifies triglyceride metabolism in hepatic steatosis induced by high-fat high-fructose feeding: a comparison with its analog resveratrol. Food and Function, 2021, 12, 3266-3279.	4.6	12
32	Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region. Scientific Reports, 2021, 11, 4363.	3.3	9
33	Germline and Somatic Whole-Exome Sequencing Identifies New Candidate Genes Involved in Familial Predisposition to Serrated Polyposis Syndrome. Cancers, 2021, 13, 929.	3.7	12
34	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology, 2021, 116, 1220-1229.	0.4	40
35	Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer. Scientific Reports, 2021, 11, 11135.	3.3	5
36	A Novel Noninvasive Method Based on Salivary Inflammatory Biomarkers for the Screening of Celiac Disease. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1511-1513.e2.	4.5	0

#	Article	IF	CITATIONS
37	P638 Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?. Journal of Crohn's and Colitis, 2021, 15, S572-S573.	1.3	0
38	DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. Journal of Crohn's and Colitis, 2021, 15, S078-S079.	1.3	0
39	Clinical outcome after antiâ€tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS longâ€term study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1277-1288.	3.7	16
40	Deep Learning Models for Colorectal Polyps. Information (Switzerland), 2021, 12, 245.	2.9	7
41	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Frontiers in Medicine, 2021, 8, 683250.	2.6	34
42	Inflammatory Potential of the Diet and Incidence of Crohn's Disease and Ulcerative Colitis in the EPIC-Spain Cohort. Nutrients, 2021, 13, 2201.	4.1	5
43	Clinical, Molecular and Genetic Characteristics of Early Onset Gastric Cancer: Analysis of a Large Multicenter Study. Cancers, 2021, 13, 3132.	3.7	11
44	Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions. Cancers, 2021, 13, 2760.	3.7	4
45	Inhibition of NAEâ€dependent protein hyperâ€NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. United European Gastroenterology Journal, 2021, 9, 848-859.	3.8	7
46	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. Molecular Diagnosis and Therapy, 2021, 25, 563-576.	3.8	5
47	A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. Gastroenterology, 2021, 161, 151-162.e1.	1.3	39
48	Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). Alimentary Pharmacology and Therapeutics, 2021, 54, 1041-1051.	3.7	6
49	The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). Antibiotics, 2021, 10, 965.	3.7	6
50	Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics, 2021, 10, 1058.	3.7	48
51	Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-Ã-vis anti-SARS-CoV-2 antibodies from a high incidence region. International Journal of Infectious Diseases, 2021, 110, 114-122.	3.3	3
52	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. Journal of Clinical Investigation, 2021, 131, .	8.2	72
53	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. Biomedicine and Pharmacotherapy, 2021, 144, 112239.	5.6	9
54	Identification of New Genes Involved in Germline Predisposition to Early-Onset Gastric Cancer. International Journal of Molecular Sciences, 2021, 22, 1310.	4.1	8

#	Article	IF	CITATIONS
55	European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics, 2021, 10, 13.	3.7	12
56	V Spanish Consensus Conference on Helicobacter pylori infection treatment. Revista Espanola De Enfermedades Digestivas, 2021, 113, .	0.3	3
57	Analysis of Post-Colonoscopy Colorectal Cancer and Its Subtypes in a Screening Programme. Cancers, 2021, 13, 5105.	3.7	6
58	V Spanish Consensus Conference on Helicobacter pylori infection treatment. GastroenterologÃa Y HepatologÃa (English Edition), 2021, , .	0.1	0
59	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut, 2021, 70, 2359-2372.	12.1	56
60	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 2021, 53, 1543-1552.	21.4	96
61	Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry. Digestive and Liver Disease, 2021, , .	0.9	2
62	Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 1788-1801.	3.0	4
63	Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer. Cancers, 2021, 13, 6216.	3.7	16
64	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. Cell Genomics, 2021, 1, 100069.	6.5	15
65	Identification of Lynch Syndrome Carriers among Patients with Small Bowel Adenocarcinoma. Cancers, 2021, 13, 6378.	3.7	0
66	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to antiâ€TNFâ€î±: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2021, 53, 1021-1029.	3.7	8
67	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases, 2020, 26, 606-616.	1.9	29
68	Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 1112-1122.	2.4	20
69	Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut, 2020, 69, 112-121.	12.1	43
70	Variation in Colonoscopy Performance Measures According to Procedure Indication. Clinical Gastroenterology and Hepatology, 2020, 18, 1216-1223.e2.	4.4	22
71	Liver iron concentration in dysmetabolic hyperferritinemia: Results from a prospective cohort of 276 patients. Annals of Hepatology, 2020, 19, 31-35.	1.5	7
72	Clinical and Pathological Characterization of Lynch-Like Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 368-374.e1.	4.4	23

#	Article	IF	CITATIONS
73	Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clinical Gastroenterology and Hepatology, 2020, 18, 89-98.	4.4	62
74	Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. Biochemical Pharmacology, 2020, 171, 113682.	4.4	7
75	Using linkage studies combined with wholeâ€exome sequencing to identify novel candidate genes for familial colorectal cancer. International Journal of Cancer, 2020, 146, 1568-1577.	5.1	8
76	CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Molecular Biology Reports, 2020, 47, 1583-1588.	2.3	13
77	Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. Clinical and Translational Gastroenterology, 2020, 11, e00218.	2.5	8
78	Bismuth quadruple regimen with tetracycline or doxycycline versus threeâ€inâ€one single capsule as thirdâ€line rescue therapy for <i>Helicobacter pylori</i> infection: Spanish data of the European <i>Helicobacter pylori</i> Registry (Hpâ€EuReg). Helicobacter, 2020, 25, e12722.	3.5	17
79	Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort. Diagnostics, 2020, 10, 1036.	2.6	1
80	Gene–Diet Interactions in Colorectal Cancer: Survey Design, Instruments, Participants and Descriptive Data of a Case–Control Study in the Basque Country. Nutrients, 2020, 12, 2362.	4.1	6
81	Comparative Effects of Pterostilbene and Its Parent Compound Resveratrol on Oxidative Stress and Inflammation in Steatohepatitis Induced by High-Fat High-Fructose Feeding. Antioxidants, 2020, 9, 1042.	5.1	23
82	Colorectal Cancer Survival in 50- to 69-Year-Olds after Introducing the Faecal Immunochemical Test. Cancers, 2020, 12, 2412.	3.7	9
83	Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome. Cancers, 2020, 12, 2225.	3.7	6
84	Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease. Journal of Hepatology, 2020, 73, S537-S538.	3.7	0
85	Body mass index and alcohol consumption are directly related with liver steatosis. Results from a prospective study of patients referred for hyperferritinemia. Annals of Hepatology, 2020, 19, 697.	1.5	1
86	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq0 0 GastroenterologÃa Y HepatologÃa, 2020, 43, 117-125.	0 rgBT /Ove 0.5	rlock 10 Tf 50 6
87	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2080-2087.	2.8	11
88	Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers, 2020, 12, 1142.	3.7	53
89	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. Liver International, 2020, 40, 1670-1685.	3.9	22
90	Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN). European Journal of Health Economics, 2020, 21, 1059-1073.	2.8	5

#	Article	IF	CITATIONS
91	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1433.	3.7	20
92	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq0 0 ( GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 117-125.	0 rgBT /Ove 0.1	rlock 10 Tf 50 0
93	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 588-596.	1.6	6
94	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	27.0	1,548
95	The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms. Cytometry Part B - Clinical Cytometry, 2020, 98, 504-515.	1.5	9
96	Helicobacter pylori firstâ€line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on HÂpylori management (Hpâ€EuReg). Helicobacter, 2020, 25, e12686.	3.5	27
97	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	4.1	63
98	Impact of the faecal immunochemical test on colorectal cancer survival. BMC Cancer, 2020, 20, 616.	2.6	16
99	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. GastroenterologAa Y HepatologAa (English Edition), 2020, 43, 332-347.	0.1	6
100	Colorectal cancer genetic variants are also associated with serrated polyposis syndrome susceptibility. Journal of Medical Genetics, 2020, 57, 677-682.	3.2	11
101	Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin. Clinical and Translational Gastroenterology, 2020, 11, e00143.	2.5	1
102	Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa. Revista Espanola De Enfermedades Digestivas, 2020, 112, 545-549.	0.3	10
103	Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test. World Journal of Gastroenterology, 2020, 26, 70-85.	3.3	8
104	Food groups, diet quality and colorectal cancer risk in the Basque Country. World Journal of Gastroenterology, 2020, 26, 4108-4125.	3.3	13
105	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. GastroenterologÃa Y HepatologÃa, 2020, 43, 79-86.	0.5	Ο
106	High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. Endoscopy, 2019, 51, 142-151.	1.8	26
107	Severe upper gastrointestinal bleeding due to eosinophilic gastritis. GastroenterologÃa Y HepatologÃa, 2019, 42, 307-308.	0.5	4
108	THU-459-Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation. Journal of Hepatology, 2019, 70, e361-e362.	3.7	0

#	Article	IF	CITATIONS
109	Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia. EBioMedicine, 2019, 46, 499-511.	6.1	128
110	Analysis of A 6-Mirna Signature in Serum from Colorectal Cancer Screening Participants as Non-Invasive Biomarkers for Advanced Adenoma and Colorectal Cancer Detection. Cancers, 2019, 11, 1542.	3.7	33
111	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. Journal of Crohn's and Colitis, 2019, 13, S328-S329.	1.3	0
112	Increased risk of thiopurineâ€related adverse events in elderly patients with IBD. Alimentary Pharmacology and Therapeutics, 2019, 50, 780-788.	3.7	40
113	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986784.	3.2	1
114	High fluorescence cell count in pleural fluids for malignant effusion screening. Clinica Chimica Acta, 2019, 499, 115-117.	1.1	6
115	Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. Journal of Crohn's and Colitis, 2019, 13, 996-1002.	1.3	52
116	Realâ€world shortâ€ŧerm effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2019, 50, 278-288.	3.7	53
117	P505 Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry. Journal of Crohn's and Colitis, 2019, 13, S364-S366.	1.3	2
118	481 INDIVIDUALIZED SURVEILLANCE FOR SERRATED POLYPOSIS SYNDROME: RESULTS FROM A PROSPECTIVE 5-YEAR INTERNATIONAL COHORT STUDY. Gastrointestinal Endoscopy, 2019, 89, AB88-AB89.	1.0	0
119	<i>Helicobacter pylori</i> pathogenicity and primary antimicrobial resistance in Northern Spain. European Journal of Clinical Investigation, 2019, 49, e13150.	3.4	15
120	Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 1380-1386.	1.3	19
121	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1492-1500.	1.3	37
122	PS-011-New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2019, 70, e10.	3.7	0
123	Gene Expression Signature in Surgical Tissues and Endoscopic Biopsies Identifies High-Risk T1 Colorectal Cancers. Gastroenterology, 2019, 156, 2338-2341.e3.	1.3	37
124	Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats. Nutrients, 2019, 11, 961.	4.1	18
125	Endoscopic surveillance after colonic polyps and colorrectal cancer resection. 2018 update. GastroenterologÃa Y HepatologÃa (English Edition), 2019, 42, 188-201.	0.1	1
126	Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver International, 2019, 39, 98-107.	3.9	171

#	Article	IF	CITATIONS
127	Mediastinal abscess, an unusual way of presentation of eosinophilic esophagitis. Allergy, Asthma and Clinical Immunology, 2019, 15, 12.	2.0	1
128	Integrated Analysis of Germline and Tumor DNA Identifies New Candidate Genes Involved in Familial Colorectal Cancer. Cancers, 2019, 11, 362.	3.7	16
129	Quality indicators and patient satisfaction in colonoscopy. GastroenterologÃa Y HepatologÃa (English) Tj ETQq1	1 0.7843 0.1	14 rgBT /Ove
130	Short article: Hormone therapy for severe gastrointestinal bleeding due to multiple angiodysplastic lesions. European Journal of Gastroenterology and Hepatology, 2019, 31, 312-315.	1.6	4
131	Low Incidence of Advanced Neoplasia in Serrated Polyposis Syndrome After (Sub)total Colectomy: Results of a 5-Year International Prospective Cohort Study. American Journal of Gastroenterology, 2019, 114, 1512-1519.	0.4	2
132	Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clinical and Translational Gastroenterology, 2019, 10, e00003.	2.5	53
133	Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia. Clinical and Translational Gastroenterology, 2019, 10, e00029.	2.5	40
134	Identification of a Novel Candidate Gene for Serrated Polyposis Syndrome Germline Predisposition by Performing Linkage Analysis Combined With Whole-Exome Sequencing. Clinical and Translational Gastroenterology, 2019, 10, e00100.	2.5	5
135	Single nucleotide polymorphisms associated with susceptibility for development of colorectal cancer: Case-control study in a Basque population. PLoS ONE, 2019, 14, e0225779.	2.5	8
136	Wnt–β-catenin signalling in liver development, health and disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 121-136.	17.8	341
137	<i>Helicobacter pylori</i> antimicrobial resistance during a 5â€year period (2013â€2017) in northern Spain and its relationship with the eradication therapies. Helicobacter, 2019, 24, e12557.	3.5	17
138	Vigilancia tras resección de pólipos de colon y de cáncer colorrectal. Actualización 2018. GastroenterologÃa Y HepatologÃa, 2019, 42, 188-201.	0.5	21
139	Differences between childhood―and adulthoodâ€onset inflammatory bowel disease: the <scp>CAROUSEL</scp> study from <scp>GETECCU</scp> . Alimentary Pharmacology and Therapeutics, 2019, 49, 419-428.	3.7	28
140	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	7.3	112
141	Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. Gut, 2019, 68, 533-546.	12.1	96
142	Video Comment on Daniel RodrÃguez-Alcalde et al Endoscopy, 2019, 51, v1-v1.	1.8	1
143	Abstract 4012: Small RNA-sequencing identifies a microRNA signature predictive of response to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer. , 2019, , .		0
144	Abstract 3148: Identification and establishment of an 18-gene redox signature for recurrence		0

prediction in colorectal cancer. , 2019, , .

#	Article	IF	CITATIONS
145	Abstract 4907: Transcriptomic profiling identifies a novel mitochondrial gene expression signature that predicts recurrence in microsatellite stable stage II and III colorectal cancer. , 2019, , .		0
146	Autoamputation of a polypoid carcinoma of the rectum. GastroenterologÃa Y HepatologÃa, 2019, 42, 486-487.	0.5	0
147	Faecal microbiota composition associates with abdominal pain in the general population. Gut, 2018, 67, gutjnl-2017-314792.	12.1	29
148	Increased Prevalence of Rare Sucrase-isomaltase PathogenicÂVariants in Irritable Bowel Syndrome Patients. Clinical Gastroenterology and Hepatology, 2018, 16, 1673-1676.	4.4	64
149	A <scp>GWAS</scp> metaâ€analysis from 5 populationâ€based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13358.	3.0	34
150	Effect of aspirin on the diagnostic accuracy of the faecal immunochemical test for colorectal advanced neoplasia. United European Gastroenterology Journal, 2018, 6, 123-130.	3.8	9
151	Rare germline copy number variants in colorectal cancer predisposition characterized by exome sequencing analysis. Journal of Genetics and Genomics, 2018, 45, 41-45.	3.9	11
152	Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA). Journal of Hepatology, 2018, 68, S435.	3.7	1
153	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology, 2018, 155, 168-179.	1.3	55
154	OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry. Journal of Crohn's and Colitis, 2018, 12, S023-S025.	1.3	4
155	MicroRNAs and extracellular vesicles in cholangiopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1293-1307.	3.8	38
156	Preguntas y errores en el diagnóstico y manejo de la anemia en pacientes con hemorragia digestiva. GastroenterologÃa Y HepatologÃa, 2018, 41, 63-76.	0.5	6
157	MicroRNAâ€506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440.	7.3	72
158	Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1335-1344.	3.8	55
159	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detectionâ€surveillance paradox. United European Gastroenterology Journal, 2018, 6, 622-629.	3.8	16
160	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. GastroenterologÃa Y HepatologÃa (English Edition), 2018, 41, 63-76.	0.1	5
161	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477.	3.8	72
162	Colorectal cancer screening program using FIT: quality of colonoscopy varies according to hospital type. Endoscopy International Open, 2018, 06, E1149-E1156.	1.8	12

#	Article	IF	CITATIONS
163	Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial. United European Gastroenterology Journal, 2018, 6, 1527-1537.	3.8	7
164	Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study. BMC Gastroenterology, 2018, 18, 155.	2.0	28
165	Extracellular Vesicles in Hepatobiliary Malignancies. Frontiers in Immunology, 2018, 9, 2270.	4.8	29
166	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. Journal of Hepatology, 2018, 69, 1371-1383.	3.7	35
167	Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PLoS ONE, 2018, 13, e0203051.	2.5	35
168	Evidence for <i><scp>PTGER</scp>4</i> , <i><scp>PSCA</scp>,</i> and <i><scp>MBOAT</scp>7</i> as risk genes for gastric cancer on the genome and transcriptome level. Cancer Medicine, 2018, 7, 5057-5065.	2.8	22
169	Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer. Cancers, 2018, 10, 300.	3.7	18
170	Genetic variation analysis in a followâ€up study of gastric cancer precursor lesions confirms the association of <i>MUC2</i> variants with the evolution of the lesions and identifies a significant association with <i>NFKB1</i> and <i>CD14</i> . International Journal of Cancer, 2018, 143, 2777-2786.	5.1	9
171	Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC). Journal of Hepatology, 2018, 68, S220.	3.7	0
172	The anti-inflammatory receptor TREM2 protects the liver from cholestatic injury in mice. Journal of Hepatology, 2018, 68, S459-S460.	3.7	0
173	Sensitization of cholangiocarcinoma to chemotherapy by SOX17- induced down-regulation of drug export pumps ABCC3 and AGCG2. Journal of Hepatology, 2018, 68, S679.	3.7	0
174	Factors related to the participation and detection of lesions in colorectal cancer screening programme-based faecal immunochemical test. European Journal of Public Health, 2018, 28, 1143-1148.	0.3	9
175	A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples. Clinical Epigenetics, 2018, 10, 53.	4.1	44
176	High fluorescence cell count in ascitic body fluids for carcinomatosis screening. Clinical Chemistry and Laboratory Medicine, 2018, 56, 272-274.	2.3	8
177	Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a populationâ€based program: A nested caseâ€control study. United European Gastroenterology Journal, 2018, 6, 755-764.	3.8	20
178	The anti-inflammatory receptor TREM2 halts the generation of HCC in mice through the inhibition of liver inflammation and hepatocyte proliferative responses. Journal of Hepatology, 2018, 68, S675-S676.	3.7	1
179	Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability, and CIMP status: Prognostic implications and response to chemotherapy Journal of Clinical Oncology, 2018, 36, 668-668.	1.6	0
180	Impact of the Colorectal Cancer Screening after 10 years in the Basque Country (Spain). European Journal of Public Health, 2018, 28, .	0.3	0

#	Article	IF	CITATIONS
181	Impact of the Colorectal Cancer Screening after 10 years in the Basque Country (Spain). European Journal of Public Health, 2018, 28, .	0.3	Ο
182	Triple synchronous gastric tumors: A rare combination diffuse adenocarcinoma, B-cell MALT lymphoma and large cell neuroendocrine carcinoma. GastroenterologÃa Y HepatologÃa, 2017, 40, 675-677.	0.5	3
183	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83.	3.7	81
184	New Advances in Polycystic Liver Diseases. Seminars in Liver Disease, 2017, 37, 045-055.	3.6	17
185	<i>TRPM8</i> polymorphisms associated with increased risk of IBS-C and IBS-M. Gut, 2017, 66, 1725-1727.	12.1	36
186	The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. International Journal of Cancer, 2017, 140, 2201-2211.	5.1	61
187	Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology, 2017, 153, 106-112.e2.	1.3	28
188	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Digestive Diseases, 2017, 35, 275-281.	1.9	8
189	Annual Fecal Immunochemical Testing is as Effective as Colonoscopy Every 5 Years for Familial Colorectal Cancer Screening. Gastroenterology, 2017, 152, S542.	1.3	3
190	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. American Journal of Gastroenterology, 2017, 112, 1135-1143.	0.4	27
191	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	7.3	218
192	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Journal of Hepatology, 2017, 66, S207-S208.	3.7	1
193	Correlation between adenoma detection rate in colonoscopy―and fecal immunochemical testingâ€based colorectal cancer screening programs. United European Gastroenterology Journal, 2017, 5, 255-260.	3.8	46
194	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology, 2017, 112, 120-131.	0.4	93
195	Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. GastroenterologÃa Y HepatologÃa, 2017, 40, 651-657.	0.5	15
196	Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma. Journal of Hepatology, 2017, 66, S462-S463.	3.7	1
197	The anti-inflammatory receptor TREM-2 protects the liver from hepatocellular carcinoma development. Journal of Hepatology, 2017, 66, S231.	3.7	0
198	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2017, 11, 1430-1439.	1.3	123

#	Article	IF	CITATIONS
199	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naÃīve and non-naÃīve patients. Journal of Gastroenterology, 2017, 52, 788-799.	5.1	50
200	Pterostilbeneâ€induced changes in gut microbiota composition in relation to obesity. Molecular Nutrition and Food Research, 2017, 61, 1500906.	3.3	88
201	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	3.7	130
202	Triple synchronous gastric tumors: A rare combination diffuse adenocarcinoma, B-cell MALT lymphoma and large cell neuroendocrine carcinoma. GastroenterologÃa Y HepatologÃa (English) Tj ETQqO O O	rgBT0/@ver	lock010 Tf 50 6
203	Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. GastroenterologÃa Y HepatologÃa (English Edition), 2017, 40, 651-657.	0.1	1
204	Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?. BMC Cancer, 2017, 17, 577.	2.6	39
205	<i>POLE</i> and <i>POLD1</i> screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget, 2017, 8, 26732-26743.	1.8	40
206	Pancreatic Cancer in Lynch Syndrome Patients. Journal of Cancer, 2017, 8, 3667-3674.	2.5	37
207	Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. Oncotarget, 2017, 8, 35848-35862.	1.8	14
208	New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets. Current Drug Targets, 2017, 18, 908-920.	2.1	7
209	Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy. Current Drug Targets, 2017, 18, 932-949.	2.1	5
210	Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World Journal of Gastroenterology, 2017, 23, 2731.	3.3	29
211	Antimicrobial susceptibility testing before first-line treatment for <i>Helicobacter pylori</i> infection in patients with dual or triple antibiotic resistance. World Journal of Gastroenterology, 2017, 23, 3367.	3.3	27
212	Effect of pravastatin on the survival of patients with advanced gastric cancer. Oncotarget, 2016, 7, 4379-4384.	1.8	15
213	Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002008.	8.4	20
214	Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Annals of Translational Medicine, 2016, 4, 134-134.	1.7	79
215	Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 894-901.	1.9	70
216	PNPLA3 p.1148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surgery for Obesity and Related Diseases, 2016, 12, 1838-1846.	1.2	60

#	Article	IF	CITATIONS
217	Immunotherapy in colorectal cancer: What have we learned so far?. Clinica Chimica Acta, 2016, 460, 78-87.	1.1	12
218	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 697-721.	0.1	27
219	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. Biochemical Pharmacology, 2016, 122, 33-41.	4.4	12
220	Effects of pterostilbene in brown adipose tissue from obese rats. Journal of Physiology and Biochemistry, 2016, 73, 457-464.	3.0	29
221	Mo1685 Rate of Detection of Serrated Lesions in Proximal Colon by Simulated Sigmoidoscopy: Comparison With Colonoscopy and Faecal Immunochemical Testing in a Multicentre, Pragmatic, Randomised Controlled Trial. Gastroenterology, 2016, 150, S750-S751.	1.3	1
222	Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. Journal of Hepatology, 2016, 65, 601-607.	3.7	41
223	Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies. Gastroenterology, 2016, 150, S877.	1.3	1
224	Tu1926 Evolution After Anti-TNF Drug Discontinuation in Patients With Inflammatory Bowel Disease (IBD): A Multicenter Long-Term Follow-Up Study. Gastroenterology, 2016, 150, S979.	1.3	1
225	Tu1996 Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicenter Study. Gastroenterology, 2016, 150, S1000-S1001.	1.3	Ο
226	The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer. European Journal of Human Genetics, 2016, 24, 1501-1505.	2.8	59
227	Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Medicine, 2016, 14, 128.	5.5	56
228	TREM-2 Protects the Liver from Immune-Mediated Hepatocellular Damage. Journal of Hepatology, 2016, 64, S149-S150.	3.7	1
229	Ursodeoxycholic Acid in Advanced Polycystic Liver Disease: A Multicenter Randomized Controlled Phase 2 Trial (Cursor). Journal of Hepatology, 2016, 64, S299.	3.7	0
230	Novel Serum Lipidomic Signature Correlates with the Grade of Steatosis Measured Biochemically and by Magnetic Resonance Imaging. Journal of Hepatology, 2016, 64, S484-S485.	3.7	0
231	SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumour Suppressor in Cholangiocarcinoma. Journal of Hepatology, 2016, 64, S569-S570.	3.7	1
232	Overexpression of Mirna-506 in Human Cholangiocytes Causes Primary Biliary Cholangitis-Like Features including Mitochondrial Dysfunction and Increased Sensitivity to Apoptosis. Journal of Hepatology, 2016, 64, S639-S640.	3.7	1
233	IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. GastroenterologÃa Y HepatologÃa, 2016, 39, 697-721.	0.5	97
234	Sa1973 Loss of Anti-TNF Drugs Into Feces and Its Impact on Anti- TNF Serum Levels and Clinical Response in Crohn's Disease (CD) Patients. Gastroenterology, 2016, 150, S421.	1.3	1

#	Article	IF	CITATIONS
235	Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines. Endoscopy, 2016, 48, 995-1002.	1.8	21
236	Antimicrobial Susceptibilityâ€Guided Therapy Versus Empirical Concomitant Therapy for Eradication of <i>Helicobacter pylori</i> in a Region with High Rate of Clarithromycin Resistance. Helicobacter, 2016, 21, 29-34.	3.5	46
237	More insight into the diversity of cholangiocyte ciliopathies. Journal of Hepatology, 2016, 65, 1083-1085.	3.7	1
238	Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Archivos De Bronconeumologia, 2016, 52, 2-62.	0.8	25
239	The Common Prosteatotic PNPLA3 (Adiponutrin) p.1148M Variant Might Protect against Gallstone Disease. Journal of Hepatology, 2016, 64, S489-S490.	3.7	0
240	SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin. Scientific Reports, 2016, 6, 32350.	3.3	39
241	Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 318-334.	1.7	125
242	Association of a let-7 miRNA binding region of <i>TGFBR1</i> with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	2.8	16
243	Tu1986 TNF-Alpha Activity in Plasma From Patients With Inflammatory Bowel Disease Under Adalimumab and Infliximab Treatment Evaluated in a Cell-Based Assay. Gastroenterology, 2016, 150, S997-S998.	1.3	Ο
244	Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for) Tj ETQqO 229-235.	0 0 rgBT /0 3.8	Overlock 10 T 7
245	Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish followâ€up multicenter study. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 953-958.	2.8	87
246	Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects. Journal of Physiology and Biochemistry, 2016, 72, 567-582.	3.0	28
247	MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 15-27.	1.5	20
248	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. American Journal of Gastroenterology, 2016, 111, 261-268.	0.4	42
249	Endoscopist characteristics that influence the quality of colonoscopy. Endoscopy, 2016, 48, 241-247.	1.8	42
250	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.9	23
251	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	29
252	Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut, 2016, 65, 1829-1837.	12.1	93

#	Article	IF	CITATIONS
253	Influence of Dopaminergic System Genetic Variation and Lifestyle Factors on Excessive Alcohol Consumption. Alcohol and Alcoholism, 2016, 51, 258-267.	1.6	10
254	Genetic Variants Associated with Colorectal Adenoma Susceptibility. PLoS ONE, 2016, 11, e0153084.	2.5	15
255	Clypican-1 in exosomes as biomarker for early detection of pancreatic cancer. Annals of Translational Medicine, 2016, 4, 64.	1.7	44
256	p-21 activated kinase 4 (PAK4) role in pancreatic cancer stem cells. Translational Cancer Research, 2016, 5, S335-S337.	1.0	0
257	P1182 : MIR-506 is upregulated by pro-inflammatory cytokines in human cholangiocytes and inhibits cell proliferation and adhesion. Journal of Hepatology, 2015, 62, S797.	3.7	Ο
258	P1317 : Efficacy of ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic liver disease: An international, multicenter, randomized controlled trial. Journal of Hepatology, 2015, 62, S848-S849.	3.7	0
259	Association of <i>PSCA</i> rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. International Journal of Cancer, 2015, 137, 1362-1373.	5.1	39
260	Colorectal cancer in a second round after a negative faecal immunochemical test. European Journal of Gastroenterology and Hepatology, 2015, 27, 813-818.	1.6	7
261	Retinoic Acid Reduces Stem Cell–Like Features in Pancreatic Cancer Cells. Pancreas, 2015, 44, 918-924.	1.1	16
262	Endoscopic surveillance in patients with multiple (10–100) colorectal polyps. Endoscopy, 2015, 48, 56-61.	1.8	1
263	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 2024-2025.	4.4	0
264	Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. Cancer, 2015, 121, 1395-1404.	4.1	51
265	Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-inflammatory Drugs, Antiplatelet Agents, or Anticoagulants. Clinical Gastroenterology and Hepatology, 2015, 13, 906-912.e2.	4.4	207
266	Diagnostic Performance of Fecal Immunochemical Test and Sigmoidoscopy for Advanced Right-Sided Colorectal Neoplasms. Digestive Diseases and Sciences, 2015, 60, 1424-1432.	2.3	11
267	Prevalence of <i>MLH1</i> constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer. Journal of Medical Genetics, 2015, 52, 498-502.	3.2	28
268	Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. American Journal of Gastroenterology, 2015, 110, 684-689.	0.4	65
269	Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Human Molecular Genetics, 2015, 24, 2914-2922.	2.9	60
270	Effectiveness of Adalimumab in Perianal Fistulas in Crohn's Disease Patients Naive to Anti-TNF Therapy. Journal of Clinical Gastroenterology, 2015, 49, 34-40.	2.2	59

#	Article	IF	CITATIONS
271	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. Journal of Crohn's and Colitis, 2015, 9, 1063-1070.	1.3	45
272	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961.	3.7	56
273	Pharmacogenomic biomarkers for colorectal cancer treatment. Cancer Treatment Communications, 2015, 4, 121-127.	0.4	1
274	Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer. Genetics in Medicine, 2015, 17, 131-142.	2.4	82
275	Association between CASP8 –652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. PLoS ONE, 2014, 9, e85538.	2.5	8
276	Population-based colorectal cancer screening: comparison of two fecal occult blood test. Frontiers in Pharmacology, 2014, 4, 175.	3.5	30
277	Effects of resveratrol and other polyphenols in hepatic steatosis. World Journal of Gastroenterology, 2014, 20, 7366.	3.3	114
278	Prevalence and Characteristics of <i>MUTYH</i> -Associated Polyposis in Patients with Multiple Adenomatous and Serrated Polyps. Clinical Cancer Research, 2014, 20, 1158-1168.	7.0	57
279	Effect of oral anticoagulants on the outcome of faecal immunochemical test. British Journal of Cancer, 2014, 110, 1334-1337.	6.4	30
280	Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Cell Death and Disease, 2014, 5, e1142-e1142.	6.3	48
281	Diagnostic accuracy of fecal immunochemical test in average―and familialâ€risk colorectal cancer screening. United European Gastroenterology Journal, 2014, 2, 522-529.	3.8	19
282	Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nature Communications, 2014, 5, 5812.	12.8	172
283	Fecal immunochemical test accuracy in familial risk colorectal cancer screening. International Journal of Cancer, 2014, 134, 367-375.	5.1	28
284	Correction: Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research, 2014, 74, 3196-3196.	0.9	0
285	MicroRNAs and cholestatic liver diseases. Current Opinion in Gastroenterology, 2014, 30, 303-309.	2.3	35
286	Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. European Journal of Gastroenterology and Hepatology, 2014, 26, 1380-1384.	1.6	25
287	Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy inKRASWild-Type Patients. BioMed Research International, 2014, 2014, 1-8.	1.9	10
288	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology, 2014, 12, 1708-1716.e4.	4.4	13

#	Article	IF	CITATIONS
289	A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. Human Genetics, 2014, 133, 525-534.	3.8	20
290	A simple and portable device for the quantification of TNF-α in human plasma by means of on-chip magnetic bead-based proximity ligation assay. Biosensors and Bioelectronics, 2014, 54, 499-505.	10.1	18
291	Clinical relevance of KRAS mutations in codon 13: Where are we?. Cancer Letters, 2014, 343, 1-5.	7.2	31
292	Surface plasmon resonance immunoassay for the detection of the TNFÎ $\pm$ biomarker in human serum. Talanta, 2014, 119, 492-497.	5.5	59
293	Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with <scp>NICE</scp> and <scp>SIGN</scp> referral criteria. Colorectal Disease, 2014, 16, O273-82.	1.4	73
294	Phenotype Characteristics of Patients With Colonic Serrated Polyposis Syndrome: A Study of 23 Cases. CirugÃa Española (English Edition), 2014, 92, 659-664.	0.1	2
295	Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata. Scandinavian Journal of Gastroenterology, 2014, 49, 1181-1190.	1.5	10
296	Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761.	17.8	80
297	Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. BMC Medicine, 2014, 12, 137.	5.5	20
298	Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes and Control, 2014, 25, 985-997.	1.8	31
299	Characteristics of Adenomas Detected by Fecal Immunochemical Test in Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1884-1892.	2.5	19
300	CaracterÃsticas fenotÃpicas de los pacientes con sÃndrome de poliposis serrada de colon: estudio de 23 casos. CirugÃa Española, 2014, 92, 659-664.	0.2	3
301	P831 MAGNETIC RESONANCE IMAGING ALLOWS QUANTITATION OF HEPATIC TRIGLYCERIDE CONCENTRATION IN HUMANS. Journal of Hepatology, 2014, 60, S347-S348.	3.7	0
302	Su1167 European Registry on H. pylori Management (Hp-EuReg): Spanish Detailed Results (Interim) Tj ETQq0 0 0	rgBT /Ov	erlock 10 Tf 5
303	P382 INHIBITION OF METALLOPROTEASE HYPERACTIVITY IN CYSTIC CHOLANGIOCYTES HALTS THE DEVELOPMENT OF POLYCYSTIC LIVER DISEASES. Journal of Hepatology, 2014, 60, S195.	3.7	0
304	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	12.1	55
305	The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals. PLoS ONE, 2014, 9, e95022.	2.5	7

306Fecal immunochemical test accuracy in average-risk colorectal cancer screening. World Journal of<br/>Gastroenterology, 2014, 20, 1038.3.354

#	ARTICLE	IF	CITATIONS
307	New genes emerging for colorectal cancer predisposition. World Journal of Gastroenterology, 2014, 20, 1961.	3.3	34
308	Embryonic stem cell factors and pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 2247.	3.3	71
309	Epigenetic Regulation of Autophagy by the Methyltransferase G9a. Molecular and Cellular Biology, 2013, 33, 3983-3993.	2.3	177
310	Clinical Subtypes and Molecular Characteristics of Serrated Polyposis Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 705-711.	4.4	36
311	Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats. Nutrition, 2013, 29, 1374-1380.	2.4	66
312	Mo1122 Relevance of Psca Rs2294008 Gene Polymorphism on Gastric Cancer Risk and Prognosis. Gastroenterology, 2013, 144, S-583-S-584.	1.3	1
313	Effect of Aspirin and Antiplatelet Drugs on the Outcome of the Fecal Immunochemical Test. Mayo Clinic Proceedings, 2013, 88, 683-689.	3.0	24
314	Circulating MicroRNAs as Biomarkers of Colorectal Cancer: Results From a Genome-Wide Profiling and Validation Study. Clinical Gastroenterology and Hepatology, 2013, 11, 681-688.e3.	4.4	157
315	Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics Journal, 2013, 13, 209-217.	2.0	37
316	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointestinal Endoscopy, 2013, 77, 381-389.e1.	1.0	125
317	Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation. Gastroenterology, 2013, 144, 926-932.e1.	1.3	189
318	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointestinal Endoscopy, 2013, 78, 333-341.e1.	1.0	62
319	Molecular markers in pancreatic cancer diagnosis. Clinica Chimica Acta, 2013, 418, 22-29.	1.1	32
320	Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. Scandinavian Journal of Gastroenterology, 2013, 48, 285-294.	1.5	6
321	SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis, 2013, 2, e61-e61.	4.9	275
322	<i><scp>BMPR1A</scp></i> mutations in earlyâ€onset colorectal cancer with mismatch repair proficiency. Clinical Genetics, 2013, 84, 94-96.	2.0	11
323	Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection, 2013, 19, 379-383.	6.0	48
324	Genetic susceptibility variants associated with colorectal cancer prognosis. Carcinogenesis, 2013, 34, 2286-2291.	2.8	18

#	Article	IF	CITATIONS
325	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. Journal of the National Cancer Institute, 2013, 105, 878-886.	6.3	25
326	BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis, 2013, 34, 314-318.	2.8	14
327	A microfluidic magnetic bead-based proximity ligation assay device for the quantification of TNF-α in human plasma. , 2013, , .		0
328	A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics, 2013, 14, 55.	2.8	36
329	Expression of <i>SLC22A1</i> variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology, 2013, 58, 1065-1073.	7.3	124
330	Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer. PLoS ONE, 2013, 8, e51810.	2.5	23
331	Alcohol consumption on pancreatic diseases. World Journal of Gastroenterology, 2013, 19, 638.	3.3	70
332	Somatic second-hit mutations leads to polycystic liver diseases. World Journal of Gastroenterology, 2013, 19, 141.	3.3	10
333	Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility. PLoS ONE, 2013, 8, e72091.	2.5	19
334	Prognosis and follow-up of 135 patients with ischemic colitis over a five-year period. World Journal of Gastroenterology, 2013, 19, 8042.	3.3	26
335	Abstract 1334: Implication of the $3\hat{a}\in^2$ UTR region of TGFÎ <sup>2</sup> R1 with MSS HNPCC and sporadic colorectal cancer , 2013, , .		0
336	Several statins increase body and liver fat accumulation in a model of metabolic syndrome. Journal of Physiology and Pharmacology, 2013, 64, 281-8.	1.1	39
337	Clinical practice Guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy, 2012, 44, 444-451.	1.8	131
338	Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. New England Journal of Medicine, 2012, 366, 697-706.	27.0	763
339	Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. British Journal of Nutrition, 2012, 107, 202-210.	2.3	137
340	Effect of Neoadjuvant Chemotherapy in Hepatic Steatosis. Chemotherapy, 2012, 58, 89-94.	1.6	6
341	Susceptibility genetic variants associated with early-onset colorectal cancer. Carcinogenesis, 2012, 33, 613-619.	2.8	35
342	Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experience. Mutagenesis, 2012, 27, 153-159.	2.6	9

#	Article	IF	CITATIONS
343	Association of alcohol dehydrogenase polymorphisms and lifeâ€style factors with excessive alcohol intake within the <scp>S</scp> panish population ( <scp>EPIC</scp> â€ <scp>S</scp> pain). Addiction, 2012, 107, 2117-2127.	3.3	11
344	Immunohistochemical alterations in invasive adenocarcinoma in endoscopically resected adenoma and factors associated with risk of residual or recurrent disease. Colorectal Disease, 2012, 14, e587-94.	1.4	3
345	MicroRNAs in biliary diseases. World Journal of Gastroenterology, 2012, 18, 6189.	3.3	30
346	Oncogenicity of the Developmental Transcription Factor Sox9. Cancer Research, 2012, 72, 1301-1315.	0.9	180
347	Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut, 2012, 61, 865-872.	12.1	172
348	A comparison of Val81Met and other polymorphisms of alcohol metabolising genes in patients and controls in Northern Spain. Alcohol, 2012, 46, 427-431.	1.7	5
349	Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5T in rats with nonalcoholic fatty liver disease. European Journal of Radiology, 2012, 81, 1122-1127.	2.6	8
350	Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews, 2012, 44, 148-172.	3.6	117
351	Su1854 Association of TP53 Arg72pro Variants With Gastric Cancer Risk in Helicobacter pylori Infected Subjects: A Nation-Wide Case-Control Study in Spain. Gastroenterology, 2012, 142, S-519.	1.3	1
352	Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotype. Mutagenesis, 2012, 27, 771-777.	2.6	53
353	A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer. PLoS ONE, 2012, 7, e45357.	2.5	164
354	Prognostic Role of Host Cyclooxygenase and Cytokine Genotypes in a Caucasian Cohort of Patients with Gastric Adenocarcinoma. PLoS ONE, 2012, 7, e46179.	2.5	9
355	Mouse models of pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 1286.	3.3	124
356	Up-regulation of microRNA 506 leads to decreased Clâ°'/HCO3â° anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology, 2012, 56, 687-697.	7.3	199
357	Highâ€dose, tenâ€day esomeprazole, amoxicillin and metronidazole triple therapy achieves high <i><scp>H</scp>elicobacter pylori</i> eradication rates. Alimentary Pharmacology and Therapeutics, 2012, 36, 190-196.	3.7	26
358	Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. Cancer Cell International, 2012, 12, 5.	4.1	9
359	Adjuvant and neoadjuvant treatment in pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 1565.	3.3	46
360	Spontaneous regression of pancreatic cancer: Real or a misdiagnosis?. World Journal of Gastroenterology, 2012, 18, 2902.	3.3	11

#	Article	IF	CITATIONS
361	c-Met in pancreatic cancer stem cells: Therapeutic implications. World Journal of Gastroenterology, 2012, 18, 5321.	3.3	35
362	Factors associated with complete endoscopic resection of an invasive adenocarcinoma in a colorectal adenoma. Revista Espanola De Enfermedades Digestivas, 2012, 104, 524-529.	0.3	3
363	Clinical patterns and outcomes of ischaemic colitis: Results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). Scandinavian Journal of Gastroenterology, 2011, 46, 236-246.	1.5	124
364	Relevance of DNA Repair Gene Polymorphisms on Gastric Cancer Susceptibility and Phenotype. Gastroenterology, 2011, 140, S-354.	1.3	1
365	Clinical and Molecular Features of the Hyperplastic Polyposis Syndrome. Gastroenterology, 2011, 140, S-260.	1.3	1
366	5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology, 2011, 140, 1174-1181.	1.3	185
367	Early Use of Azathioprine Has a Steroid Sparing Effect on Recently Diagnosed Crohn's Disease Patients. Gastroenterology, 2011, 140, S-109.	1.3	16
368	Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC). Gastroenterology, 2011, 140, S-820-S-821.	1.3	1
369	Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World Journal of Gastroenterology, 2011, 17, 1674.	3.3	73
370	The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Alimentary Pharmacology and Therapeutics, 2011, 33, 585-591.	3.7	137
371	Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2011, 34, 544-554.	3.7	77
372	Alcohol-Metabolizing Enzyme Gene Polymorphisms in the Basque Country, Morocco, and Ecuador. Alcoholism: Clinical and Experimental Research, 2011, 35, 879-884.	2.4	6
373	Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome. BMC Medical Genetics, 2011, 12, 12.	2.1	7
374	A two-phase case–control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. British Journal of Cancer, 2011, 105, 870-875.	6.4	20
375	Esophagitis in a High H. pylori Prevalence Area: Severe Disease Is Rare but Concomitant Peptic Ulcer Is Frequent. PLoS ONE, 2011, 6, e25051.	2.5	1
376	Diagnosis, treatment and follow-up of gastric carcinoid tumors: Analysis of 14 cases. Revista Espanola De Enfermedades Digestivas, 2011, 103, 493-494.	0.3	2
377	Diagnosis of Whipple's disease using molecular biology techniques. Revista Espanola De Enfermedades Digestivas, 2011, 103, 213-7.	0.3	3
378	Disease-specific health-related quality of life in patients with esophageal achalasia before and after therapy. Neurogastroenterology and Motility, 2010, 22, 739-745.	3.0	10

#	Article	IF	CITATIONS
379	Malignant colorectal polyps. World Journal of Gastroenterology, 2010, 16, 3103.	3.3	195
380	Aberrant Gene Promoter Methylation Associated with Sporadic Multiple Colorectal Cancer. PLoS ONE, 2010, 5, e8777.	2.5	59
381	MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer. Clinical Cancer Research, 2010, 16, 5402-5413.	7.0	80
382	Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut, 2010, 59, 1340-1346.	12.1	168
383	Inflammatory Mediators of Hepatic Steatosis. Mediators of Inflammation, 2010, 2010, 1-7.	3.0	86
384	Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study. Journal of Crohn's and Colitis, 2010, 4, 629-636.	1.3	24
385	Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype. Gastroenterology, 2010, 139, 788-796.e6.	1.3	47
386	Biochemical determination of lipid content in hepatic steatosis by the Soxtec method. World Journal of Gastroenterology, 2010, 16, 1495.	3.3	16
387	Colorectal cancer prognosis twenty years later. World Journal of Gastroenterology, 2010, 16, 862-7.	3.3	28
388	Pyogenic versus amoebic liver abscesses: A comparative clinical study in a series of 58 patients. Revista Espanola De Enfermedades Digestivas, 2010, 102, 90-9.	0.3	33
389	The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. European Journal of Cancer, 2009, 45, 365-373.	2.8	179
390	S1108 Hepatitis B and C Reactivation in Inflammatory Bowel Disease Patients Treated with Immunosuppressive Therapy. A Nationwide Multicenter Study. Gastroenterology, 2009, 136, A-190.	1.3	0
391	Time Trends and Impact of Upper and Lower Gastrointestinal Bleeding and Perforation in Clinical Practice. American Journal of Gastroenterology, 2009, 104, 1633-1641.	0.4	502
392	Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study. American Journal of Gastroenterology, 2009, 104, 57-63.	0.4	130
393	M1250 Development and Validation of a Disease-Specific Health-Related Quality of Life (HRQL) Questionnaire for Esophageal Achalasia (EA). Gastroenterology, 2009, 136, A-382.	1.3	1
394	Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterology, 2008, 8, 40.	2.0	180
395	Ten-Day Sequential Treatment forHelicobacter pyloriEradication in Clinical Practice. American Journal of Gastroenterology, 2008, 103, 2220-2223.	0.4	67
396	Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. Journal of Medical Genetics, 2008, 45, 557-563.	3.2	61

#	Article	IF	CITATIONS
397	Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. Gut, 2007, 56, 1714-1718.	12.1	85
398	Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants. American Journal of Gastroenterology, 2007, 102, 507-515.	0.4	264
399	Gastric Cancer Susceptibility Is Not Linked to Pro-and Anti-Inflammatory Cytokine Gene Polymorphisms in Whites: A Nationwide Multicenter Study in Spain. American Journal of Gastroenterology, 2007, 102, 1878-1892.	0.4	117
400	Effects of longâ€ŧerm cycloâ€oxygenase 2 selective and acid inhibition on Barrett's oesophagus. Alimentary Pharmacology and Therapeutics, 2007, 26, 913-923.	3.7	15
401	Littoral-cell angioma of the spleen: A case report. World Journal of Gastroenterology, 2007, 13, 6603.	3.3	7
402	Cytomegalovirus hepatitis and myopericarditis. World Journal of Gastroenterology, 2007, 13, 647.	3.3	31
403	Littoral-cell angioma of the spleen: A case report. World Journal of Gastroenterology, 2007, 13, 6603.	3.3	17
404	Anastrozole-induced hepatotoxicity. European Journal of Gastroenterology and Hepatology, 2006, 18, 1233-1234.	1.6	23
405	Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterology, 2006, 6, 35.	2.0	54
406	Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of Recommendations. American Journal of Gastroenterology, 2006, 101, 1104-1111.	0.4	36
407	Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut, 2006, 55, 848-855.	12.1	199
408	MRI and endoscopic ultrasonography in the staging of gastric cancer. Revista Espanola De Enfermedades Digestivas, 2006, 98, 582-90.	0.3	23
409	Seven versus Ten Days of Rabeprazole Triple Therapy for Helicobacter pylori Eradication: A Multicenter Randomized Trial. American Journal of Gastroenterology, 2005, 100, 1696-1701.	0.4	57
410	The value of colonoscopy to assess rectal bleeding in patients referred from Primary Care Units. Revista Espanola De Enfermedades Digestivas, 2005, 97, 870-6.	0.3	10
411	The Prevalence of Peptic Ulcer not Related to <i>Helicobacter pylori</i> or Nonâ€Steroidal Antiâ€Inflammatory Drug Use is Negligible in Southern Europe. Helicobacter, 2004, 9, 249-254.	3.5	78
412	'Rescue' Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures. Helicobacter, 2003, 8, 90-94.	3.5	97
413	Sonographic findings of hepatic lesions in human fascioliasis. Journal of Clinical Ultrasound, 2003, 31, 358-363.	0.8	25
414	MRCP in the diagnosis of iatrogenic bile duct injury. NMR in Biomedicine, 2003, 16, 475-478.	2.8	31

#	Article	IF	CITATIONS
415	Comparison between magnetic resonance cholangiopancreatography and ERCP for evaluation of the pancreatic duct. American Journal of Gastroenterology, 2002, 97, 347-353.	0.4	62
416	Role of Magnetic Resonance Cholangiopancreatography in Patients With Suspected Choledocholithiasis. Mayo Clinic Proceedings, 2002, 77, 422-428.	3.0	34
417	Magnetic Resonance Cholangiography Versus Ultrasound in the Evaluation of the Gallbladder. Journal of Clinical Gastroenterology, 2002, 34, 233-236.	2.2	25
418	Role of Magnetic Resonance Cholangiopancreatography in Patients With Suspected Choledocholithiasis. Mayo Clinic Proceedings, 2002, 77, 422-428.	3.0	46
419	Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Alimentary Pharmacology and Therapeutics, 2002, 16, 577-586.	3.7	37
420	Suspected choledocholithiasis: EUS, magnetic resonance cholangiopancreatography, or intraoperative cholecystectomy?. Gastrointestinal Endoscopy, 2002, 56, 951-954.	1.0	3
421	Squamous metaplasia of the rectum and sigmoid colon. Gastrointestinal Endoscopy, 2001, 53, 255-256.	1.0	6
422	The rendezvous technique for the treatment of choledocholithiasis. Gastrointestinal Endoscopy, 2001, 54, 511-513.	1.0	108
423	Efficacy and Tolerability of Three Regimens for Helicobacter pylori Eradication. Clinical Drug Investigation, 2001, 21, 1-7.	2.2	4
424	Squamous cell carcinoma of the oesophagus in a patient with Klippel–Trenaunay syndrome. European Journal of Gastroenterology and Hepatology, 2001, 13, 1107-1110.	1.6	2
425	Bochdalek's Hernia in Adults. Journal of Clinical Gastroenterology, 2001, 32, 155-157.	2.2	39
426	The Effects of Alcohol Consumption Upon The Gastrointestinal Tract. American Journal of Gastroenterology, 2000, 95, 3374-3382.	0.4	263
427	The effects of alcohol consumption upon the gastrointestinal tract. American Journal of Gastroenterology, 2000, 95, 3374-3382.	0.4	4
428	Ranitidine Bismuth Citrate Plus Azithromycin for Helicobacter pylori Eradication. Journal of Clinical Gastroenterology, 2000, 30, 337-338.	2.2	5
429	Acute Abdomen Due to Perforation of Colon by Ingested Chicken Bone: Diagnosis and Endoscopic Treatment. American Journal of Gastroenterology, 1999, 94, 3069-3071.	0.4	4
430	Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet, The, 1999, 353, 1272-1273.	13.7	2
431	In Vitro Bactericidal Effect of Wine Against Helicobacter pylori. American Journal of Gastroenterology, 1998, 93, 1392.	0.4	31
432	Esophageal Crohn's Disease With Esophagopleural Fistula. Endoscopy, 1998, 30, S109-S109.	1.8	9

#	Article	IF	CITATIONS
433	Antibacterial Activity of Wine Against Salmonella enteritidis pH or Alcohol?. Journal of Clinical Gastroenterology, 1998, 27, 179-180.	2.2	23
434	Ischemic hepatitis secondary to the spontaneous rupture of a hepatocellular carcinoma in a patient with cirrhosis. Liver, 1996, 16, 147-150.	0.1	0
435	Clinical Image. CT Findings of Pancreatic Hydatid Disease. Journal of Computer Assisted Tomography, 1996, 20, 815.	0.9	2
436	Ulcerative Colitis Associated with Acute Pancreatitis and Platelet Aggregates. Journal of Clinical Gastroenterology, 1996, 23, 77-78.	2.2	11
437	Response to Dr. Dantas: occasional dysphagia for solid foods. American Journal of Gastroenterology, 1996, 91, 816-7.	0.4	0
438	Possible Association of Acute Pancreatitis with Naproxen. Journal of Clinical Gastroenterology, 1995, 21, 258.	2.2	12
439	Primary malignant melanoma of the esophagus. Ecological Management and Restoration, 0, 13, 320-323.	0.4	2
440	Esofagitis Eosinofilikoaren RNA bidezko diagnostiko ez inbaditzailerako proposamen berria. , 0, , .		0